TOT BIOPHARM International Company Limited (HKG:1875)

HKG:1875 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	381.26	351.6	417.77	152.81	225.53
Short-Term Investments	-	-	3.18	2.58	2.6
Trading Asset Securities	-	-	40.28	-	-
Cash & Short-Term Investments	381.26	351.6	461.23	155.38	228.13
Cash Growth	8.43%	-23.77%	196.84%	-31.89%	-60.07%
Accounts Receivable	192.76	140.71	58.4	23.69	2.44
Other Receivables	21.98	51.76	39.16	79.92	1.72
Receivables	214.74	192.46	97.56	103.6	4.16
Inventory	122.27	131.92	111.43	40.85	13.34
Prepaid Expenses	5.14	5.79	0.42	2.92	-
Restricted Cash	16.34	4.37	3	-	-
Other Current Assets	3.53	7.03	3.16	3.21	3.6
Total Current Assets	743.28	693.18	676.8	305.96	249.23
Property, Plant & Equipment	736.55	710.06	480.34	323.4	311.01
Long-Term Investments	-	-	-	1.48	8.08
Other Intangible Assets	7.04	8.84	4.65	5.12	3.23
Long-Term Accounts Receivable	13.94	-	-	-	-
Other Long-Term Assets	7.96	14.03	100.25	74.29	69.65
Total Assets	1,509	1,426	1,262	710.26	641.18
Accounts Payable	43.31	35.71	25.98	28.21	18.01
Accrued Expenses	212.8	221.97	99.72	19.9	11.41
Current Portion of Long-Term Debt	69.59	41.6	75.5	146.19	-
Current Portion of Leases	1.28	1.17	1.55	1.46	1.32
Current Income Taxes Payable	1.8	1.66	2.54	-	-
Current Unearned Revenue	29.41	12.06	19.56	22.2	9.1
Other Current Liabilities	57.19	68.32	50.49	42.84	12.91
Total Current Liabilities	415.36	382.49	275.35	260.81	52.74
Long-Term Debt	324.43	302.69	212.13	59.78	-
Long-Term Leases	0.18	0.19	0.35	1.14	6.08
Long-Term Unearned Revenue	6.82	11	11	11	-
Other Long-Term Liabilities	32.33	43.05	47.77	42.45	-
Total Liabilities	779.12	739.42	546.59	375.17	58.83
Common Stock	2,297	2,297	2,297	1,893	1,874
Retained Earnings	-1,649	-1,683	-1,646	-1,596	-1,342
Comprehensive Income & Other	80.68	72.47	61.91	37.8	49.5
Total Common Equity	729.66	686.69	713.88	335.09	582.36
Minority Interest	-	-	1.56	-	-
Shareholders' Equity	729.66	686.69	715.44	335.09	582.36
Total Liabilities & Equity	1,509	1,426	1,262	710.26	641.18
Total Debt	395.47	345.65	289.53	208.57	7.41
Net Cash (Debt)	-14.21	5.95	171.7	-53.18	220.73
Net Cash Growth	-	-96.54%	-	-	-55.52%
Net Cash Per Share	-0.02	0.01	0.27	-0.09	0.39
Filing Date Shares Outstanding	772.79	772.79	772.79	615.23	600.47
Total Common Shares Outstanding	772.79	772.79	772.79	615.23	600.47
Working Capital	327.91	310.69	401.45	45.16	196.48
Book Value Per Share	0.94	0.89	0.92	0.54	0.97
Tangible Book Value	722.61	677.85	709.23	329.97	579.13
Tangible Book Value Per Share	0.94	0.88	0.92	0.54	0.96
Buildings	-	197.7	110.9	119.74	150.55
Machinery	-	392.91	221.5	215.69	191.35
Construction In Progress	-	220.24	241.41	65.98	45.55
Order Backlog	191	-	-	-	-

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.